טוען...
Alzheimer’s disease drug-development pipeline: few candidates, frequent failures
INTRODUCTION: Alzheimer’s disease (AD) is increasing in frequency as the global population ages. Five drugs are approved for treatment of AD, including four cholinesterase inhibitors and an N-methyl-D-aspartate (NMDA)-receptor antagonist. We have an urgent need to find new therapies for AD. METHODS:...
שמור ב:
| Main Authors: | , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BioMed Central
2014
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4095696/ https://ncbi.nlm.nih.gov/pubmed/25024750 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/alzrt269 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|